Amorfix Life Sciences discovers common link between ALS and Alzheimer's Disease



    TSX: AMF

    TORONTO, Nov. 27 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company
focused on treatments and diagnostics for brain-wasting diseases, today
announced the discovery of misfolded superoxide dismutase 1 (SOD1) protein in
the brains of people with Alzheimer's Disease. This breakthrough result
suggests that SOD1 is a common link between the two brain-wasting diseases,
Alzheimer's and ALS, also known as Lou Gehrig's Disease. SOD1 has a
"Jekyll-and-Hyde" nature as it normally plays an important protective role in
detoxifying free radicals in the body, but when misfolded can create lethal
oxidative free radicals.
    "Amorfix previously reported results from pilot studies showing our
proprietary antibodies and vaccines targeting misfolded SOD1 showed life
extension in a mouse model of ALS. Amorfix will now investigate the use of
these same or similar agents to treat Alzheimer's disease," said Dr. Neil
Cashman, Chief Scientific Officer of Amorfix. "Evidence of free radical
toxicity has been observed in Alzheimer's disease for many years and the
discovery of the presence of misfolded SOD1 strongly suggests this toxicity is
associated with SOD1."
    "The early success of our ALS therapeutic program targeting misfolded
SOD1 together with the growing scientific evidence from external sources,
gives us confidence to expand our product pipeline to include a treatment for
Alzheimer's Disease," said Dr. George Adams, CEO of Amorfix Life Sciences.
"While many companies are developing potential Alzheimer's disease treatments
focused on the Abeta amyloid protein, Amorfix will use a novel approach based
on Dr. Cashman's pioneering research on the importance of SOD1."
    Amorfix's technology targets misfolded SOD1 through two approaches, a
passive infusion of manufactured monoclonal antibodies and an active
immunization approach designed to elicit the production of similar antibodies
by the patient's own body. Amorfix's technology is based on the premise that
the misfolding and aggregation of SOD1 is a principal agent in the death of
neurons that occurs in brain-wasting diseases. Amorfix believes that if
misfolded SOD1 can be specifically recognized and its toxic activity
neutralized by antibodies, brain-wasting diseases could be effectively
treated.
    Amorfix's technology related to the role of SOD1 in ALS and Alzheimer's
is covered by patent applications including one recently published entitled,
"Methods and Compositions to treat and Detect Misfolded-SOD1 Mediated
Diseases". The patent application relates to the methods and compositions for
treating and detecting conditions, disease and disorders mediated by
non-native SOD1.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.





For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 482-3813, Fax: (416) 482-3811,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 482-3814, Fax: (416) 482-3811,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890